Literature DB >> 3921386

Arachidonic acid-induced platelet aggregation and prostanoid formation in whole blood in relation to plasma concentration of indomethacin.

E Vinge.   

Abstract

A single oral dose of indomethacin 1 mg/kg was given to 6 male and 6 female volunteers. The formation of thromboxane B2 (TXB2) and 6-keto-prostaglandin F1 alpha (6-keto-PGF1 alpha) in clotting whole blood was measured by radioimmunoassay, and platelet aggregation induced by arachidonic acid (AA) was measured with a plasma aggregometer. The results were related to the concomitant plasma concentration of indomethacin. The maximum plasma concentration ranged between 3.24 and 8.11 micrograms/ml and the elimination half-life between 4 and 11 h. Formation of the prostanoids was reversibly inhibited, with maximum suppression when the drug concentration in plasma exceeded 0.5-1.0 microgram/ml; the IC50 was approximately 0.1 microgram/ml. Platelet aggregation was also reversibly inhibited. The correlation between the formation of prostanoids and the different phases of the aggregatory response to exogenous AA is discussed.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3921386     DOI: 10.1007/bf00609686

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  18 in total

1.  Platelet aggregation induced by arachidonic acid is accompanied by release of potential inflammatory mediators distinct from PGE2 and PGF2.

Authors:  B B Vargaftig; P Zirinis
Journal:  Nat New Biol       Date:  1973-07-25

2.  Aspirin selectively inhibits prostaglandin production in human platelets.

Authors:  J B Smith; A L Willis
Journal:  Nat New Biol       Date:  1971-06-23

3.  Blood can synthesize prostacyclin.

Authors:  M A Orchard; I A Blair; C T Dollery; P J Lewis
Journal:  Lancet       Date:  1983-09-03       Impact factor: 79.321

4.  Endogenous prostacyclin biosynthesis and platelet function during selective inhibition of thromboxane synthase in man.

Authors:  G A FitzGerald; A R Brash; J A Oates; A K Pedersen
Journal:  J Clin Invest       Date:  1983-10       Impact factor: 14.808

5.  Low dose aspirin and inhibition of thromboxane B2 production in healthy subjects.

Authors:  C Patrono; G Ciabattoni; E Pinca; F Pugliese; G Castrucci; A De Salvo; M A Satta; B A Peskar
Journal:  Thromb Res       Date:  1980 Feb 1-15       Impact factor: 3.944

6.  A comparison of the inhibitory effects of melatonin and indomethacin on platelet aggregation and thromboxane release.

Authors:  C M Leach; G D Thorburn
Journal:  Prostaglandins       Date:  1980-07

7.  Determination of indomethacin in serum by an extractive alkylation technique and gas-liquid chromatography.

Authors:  K M Jensen
Journal:  J Chromatogr       Date:  1978-06-01

8.  Investigation on a selective non-prostanoic thromboxane antagonist, BM 13.177, in human platelets.

Authors:  H Patscheke; K Stegmeier
Journal:  Thromb Res       Date:  1984-02-01       Impact factor: 3.944

9.  Prolonged inhibition of ex vivo sodium arachidonate-induced platelet aggregation and malondialdehyde (MDA) production by sulphinpyrazone (Anturan) in man.

Authors:  E D Maguire; G F Pay; R B Wallis; A M White
Journal:  Thromb Res       Date:  1981-02-01       Impact factor: 3.944

10.  Prostaglandin and thromboxane biosynthesis inhibitors.

Authors:  R J Gryglewski
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1977       Impact factor: 3.000

View more
  2 in total

1.  The effect of indomethacin and enalapril on the cutaneous response to bradykinin.

Authors:  L G McAlpine; N C Thomson
Journal:  Br J Clin Pharmacol       Date:  1989-06       Impact factor: 4.335

2.  Cutaneous blood flow changes and weal induced by intradermal bradykinin following pretreatment with indomethacin and captopril.

Authors:  T C Wa; E D Cooke; P Turner
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.